Significant effects of <em>Ganoderma lucidum</em> polysaccharide on lipid metabolism in diabetes may be associated with the activation of the FAM3C‑HSF1‑CAM signaling pathway

Pan,Rui; Lou,Jian; Wei,Ling

doi:10.3892/etm.2021.10252

Significant effects of Ganoderma lucidum polysaccharide on lipid metabolism in diabetes may be associated with the activation of the FAM3C‑HSF1‑CAM signaling pathway

Authors:
- Rui Pan
- Jian Lou
- Ling Wei
View Affiliations

Affiliations: Department of Nutrition, Yuxi People's Hospital of Kunming, Yuxi, Yunnan 653100, P.R. China, Department of Clinical Nutrition, Second People's Hospital of Yunnan Province, Kunming, Yunnan 650051, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/etm.2021.10252
Article Number: 820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes is a threat to patient health worldwide. Type 2 diabetes (T2DM), one of the two main types of diabetes, is a long‑term metabolic disease caused by heredity and environmental factors. It has been reported that Ganoderma lucidum polysaccharide (GLP) significantly decreased the concentration of blood glucose, promoted insulin secretion, improved glucose tolerance and regulated the concentration of blood lipids. In the present study, a T2DM model was established in db/db mice, following which T2DM mice were treated with GLP (100 and 400 mg/kg) for 8 weeks, with MET used as the positive control. The glycosylated hemoglobin (HbAlc) and fasting blood glucose (FBG) levels, and diabetes‑associated clinical chemistry indexes were detected in the blood and serum of each mouse. Hematoxylin and eosin, and oil red O staining were performed on the livers of each mouse to evaluate the level of liver fat. The expression levels of family with sequence similarity 3 (FAM3C), heat shock factor 1 (HSF1), calmodulin (CaM), AKT and phosphorylated (p)‑AKT were detected in the hepatocytes of T2DM mice using reverse transcription‑quantitative PCR and western blotting. The results demonstrated that the unbalanced levels of HbAlc, FBG and diabetes‑related index in T2DM mice were significantly improved by treatment with GLP. Lipid droplets in the hepatocytes of mice shrank in the GLP groups compared with the model control group. The expression levels of FAM3C, HSF1, CaM and p‑AKT/AKT in the hepatocytes of T2DM mice were significantly increased following treatment with GLP. In conclusion, GLP exerted significant effects on lipid metabolism in diabetes, which may be associated with the activation of the FAM3C‑HSF1‑CaM signaling pathway.

View Figures

View References

1	Zhu J, Zhang X, Zhang X, Dong M, Wu J, Dong Y, Chen R, Ding X, Huang C, Zhang Q and Zhou W: The burden of ambient air pollution on years of life lost in Wuxi, China, 2012-2015: A time-series study using a distributed lag non-linear model. Environ Pollut. 224:689–697. 2017.PubMed/NCBI View Article : Google Scholar
2	Patil P, Mandal S, Tomar SK and Anand S: Food protein-derived bioactive peptides in management of type 2 diabetes. Eur J Nutr. 54:863–880. 2015.PubMed/NCBI View Article : Google Scholar
3	Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, et al: Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary. Endocr Pract. 25:69–100. 2019.PubMed/NCBI View Article : Google Scholar
4	He K, Shi JC and Mao XM: Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag. 10:505–511. 2014.PubMed/NCBI View Article : Google Scholar
5	Abe M, Okada K, Maruyama T, Maruyama N and Matsumoto K: Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother. 11:169–176. 2010.PubMed/NCBI View Article : Google Scholar
6	Kirschner LS, Qamri Z, Kari S and Ashtekar A: Mouse models of thyroid cancer: A 2015 update. Mol Cell Endocrinol. 421:18–27. 2016.PubMed/NCBI View Article : Google Scholar
7	Ali MY, Zaib S, Rahman MM, Jannat S, Iqbal J, Park SK and Chang MS: Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells. Chem Biol Interact. 305:180–194. 2019.PubMed/NCBI View Article : Google Scholar
8	Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS and Ryu KS: Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem. 49:4208–4213. 2001.PubMed/NCBI View Article : Google Scholar
9	Chehade JM and Mooradian AD: A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 60:95–113. 2000.PubMed/NCBI View Article : Google Scholar
10	Lorenzo PI, Juárez-Vicente F, Cobo-Vuilleumier N, Garcia-Dominguez M and Gauthier BR: The diabetes-linked transcription factor PAX4: From gene to functional consequences. Genes (Basel). 8(101)2017.PubMed/NCBI View Article : Google Scholar
11	Omori K, Kobayashi E, Rawson J, Takahashi M and Mullen Y: Mechanisms of islet damage mediated by pancreas cold ischemia/rewarming. Cryobiology. 73:126–134. 2016.PubMed/NCBI View Article : Google Scholar
12	Beattie GM, Leibowitz G, Lopez AD, Levine F and Hayek A: Protection from cell death in cultured human fetal pancreatic cells. Cell Transplant. 9:431–438. 2000.PubMed/NCBI View Article : Google Scholar
13	Xue YF, Guo CZ, Hu F, Sun DM, Liu JH and Mao SY: Molecular mechanisms of lipid metabolism disorder in livers of ewes with pregnancy toxemia. Animal. 13:992–999. 2019.PubMed/NCBI View Article : Google Scholar
14	Kaneko YK: Development and analysis of novel therapeutic targets to improve pancreatic β-cell function in type 2 diabetes. Yakugaku Zasshi. 136:1623–1629. 2016.PubMed/NCBI View Article : Google Scholar : (In Japanese).
15	Langley AK, Suffoletta TJ and Jennings HR: Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy. 27:1163–1180. 2007.PubMed/NCBI View Article : Google Scholar
16	Somtimuang C, Olatunji OJ and Ovatlarnporn C: Evaluation of in vitro α-amylase and α-glucosidase inhibitory potentials of 14 medicinal plants constituted in thai folk antidiabetic formularies. Chem Biodivers. 15(e1800025)2018.PubMed/NCBI View Article : Google Scholar
17	Wu H, Liu J, Lou Q, Liu J, Shen L, Zhang M, Lv X, Gu M and Guo X: Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. Medicine (Baltimore). 96(e7533)2017.PubMed/NCBI View Article : Google Scholar
18	Xu J and Rajaratnam R: Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol. 16(18)2017.PubMed/NCBI View Article : Google Scholar
19	Laoud A, Ferkous F, Maccari L, Maccari G, Saihi Y and Kraim K: Identification of novel nt-MGAM inhibitors for potential treatment of type 2 diabetes: Virtual screening, atom based 3D-QSAR model, docking analysis and ADME study. Comput Biol Chem. 72:122–135. 2018.PubMed/NCBI View Article : Google Scholar
20	Men P, Li XT, Tang HL and Zhai SD: Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 13(e0197321)2018.PubMed/NCBI View Article : Google Scholar
21	Min SH, Yoon JH, Hahn S and Cho YM: Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. J Diabetes Investig. 9:893–902. 2018.PubMed/NCBI View Article : Google Scholar
22	Chiefari E, Arcidiacono B, Foti D and Brunetti A: Gestational diabetes mellitus: An updated overview. J Endocrinol Invest. 40:899–909. 2017.PubMed/NCBI View Article : Google Scholar
23	Chen Y, Qiao J, Luo J, Wu F, Meng G, Chen H, Zheng H and Xu J: Effects of Ganoderma lucidum polysaccharides on advanced glycation end products and receptor of aorta pectoralis in T2DM rats. Zhongguo Zhong Yao Za Zhi. 36:624–627. 2011.PubMed/NCBI(In Chinese).
24	Teng BS, Wang CD, Yang HJ, Wu JS, Zhang D, Zheng M, Fan ZH, Pan D and Zhou P: A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agric Food Chem. 59:6492–6500. 2011.PubMed/NCBI View Article : Google Scholar
25	Tamez-Pérez HE, Gonzalez-Guajardo EE and Tamez-Peña AL: Re: Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary. Endocr Pract. 25(622)2019.PubMed/NCBI View Article : Google Scholar
26	Shen L, Ao L, Xu H, Shi J, You D, Yu X, Xu W, Sun J and Wang F: Poor short-term glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: A prospective, single-center, observational study. BMC Endocr Disord. 19(29)2019.PubMed/NCBI View Article : Google Scholar
27	Zhang X, Yang W, Wang J, Meng Y, Guan Y and Yang J: FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes. Metabolism. 81:71–82. 2018.PubMed/NCBI View Article : Google Scholar
28	Chen Z, Wang J, Yang W, Chen J, Meng Y, Feng B, Chi Y, Geng B, Zhou Y, Cui Q and Yang J: FAM3C activates HSF1 to suppress hepatic gluconeogenesis and attenuate hyperglycemia of type 1 diabetic mice. Oncotarget. 8:106038–106049. 2017.PubMed/NCBI View Article : Google Scholar
29	Zhao X, Li J, Liu Y, Wu D, Cai P and Pan Y: Structural characterization and immunomodulatory activity of a water soluble polysaccharide isolated from Botrychium ternatum. Carbohydr Polym. 171:136–142. 2017.PubMed/NCBI View Article : Google Scholar
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
31	Liu Y, Zhang C, Du J, Jia R, Cao L, Jeney G, Teraoka H, Xu P and Yin G: Protective effect of Ganoderma lucidum polysaccharide against carbon tetrachloride-induced hepatic damage in precision-cut carp liver slices. Fish Physiol Biochem. 43:1209–1221. 2017.PubMed/NCBI View Article : Google Scholar
32	Rashad FM, Kattan MHE, Fathy HM, El-Fattah DAA, Tohamy ME and Farahat AA: Recycling of agro-wastes for Ganoderma lucidum mushroom production and Ganoderma post mushroom substrate as soil amendment. Waste Manag. 88:147–159. 2019.PubMed/NCBI View Article : Google Scholar
33	Wan Y, Wang Q and Prud'homme GJ: GABAergic system in the endocrine pancreas: A new target for diabetes treatment. Diabetes Metab Syndr Obes. 8:79–87. 2015.PubMed/NCBI View Article : Google Scholar
34	Singh P, Jayaramaiah RH, Agawane SB, Vannuruswamy G, Korwar AM, Anand A, Dhaygude VS, Shaikh ML, Joshi RS, Boppana R, et al: Potential dual role of eugenol in inhibiting advanced glycation end products in diabetes: Proteomic and mechanistic insights. Sci Rep. 6(18798)2016.PubMed/NCBI View Article : Google Scholar
35	Xue H, Qiao J, Meng G, Wu F, Luo J, Chen H, Zheng H and Xu J: Effect of Ganoderma lucidum polysaccharides on hemodynamic and antioxidation in T2DM rats. Zhongguo Zhong Yao Za Zhi. 35:339–343. 2010.PubMed/NCBI View Article : Google Scholar : (In Chinese).
36	Li HN, Zhao LL, Zhou DY and Chen DQ: Ganoderma lucidum polysaccharides ameliorates hepatic steatosis and oxidative stress in db/db mice via targeting nuclear factor E2 (erythroid-derived 2)-related factor-2/heme oxygenase-1 (HO-1) pathway. Med Sci Monit. 26(e921905)2020.PubMed/NCBI View Article : Google Scholar
37	Chen M, Xiao D, Liu W, Song Y, Zou B, Li L, Li P, Cai Y, Liu D, Liao Q and Xie Z: Intake of Ganoderma lucidum polysaccharides reverses the disturbed gut microbiota and metabolism in type 2 diabetic rats. Int J Biol Macromol. 155:890–902. 2020.PubMed/NCBI View Article : Google Scholar
38	Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, Tseng SF, Wu TR, Chen YY, Young JD and Lai HC: Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 6(7489)2015.PubMed/NCBI View Article : Google Scholar
39	Ma HT, Hsieh JF and Chen ST: Anti-diabetic effects of Ganoderma lucidum. Phytochemistry. 114:109–113. 2015.PubMed/NCBI View Article : Google Scholar
40	Adeyemi WJ, Olayaki LA, Abdussalam TA, Fabiyi TO, Raji TL and Adetunji AA: Co-administration of omega-3 fatty acids and metformin showed more desirable effects than the single therapy on indices of bone mineralisation but not gluco-regulatory and antioxidant markers in diabetic rats. Biomed Pharmacother. 121(109631)2020.PubMed/NCBI View Article : Google Scholar
41	Xiao C, Wu QP, Cai W, Tan JB, Yang XB and Zhang JM: Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice. Arch Pharm Res. 35:1793–1801. 2012.PubMed/NCBI View Article : Google Scholar
42	Xiao C, Wu Q, Zhang J, Xie Y, Cai W and Tan J: Antidiabetic activity of Ganoderma lucidum polysaccharides F31 down-regulated hepatic glucose regulatory enzymes in diabetic mice. J Ethnopharmacol. 196:47–57. 2017.PubMed/NCBI View Article : Google Scholar